| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Common Stock | 150K | $122K | $0.81 | 09 Mar 2023 | Direct |
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Common Stock | 1.45K | $1.17K | $0.81 | 09 Mar 2023 | Tasro Consulting, LLC 401(k) Plan, Kenneth Marshall Trustee, f/b/o Kenneth Marshall |
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Performance Stock Units | 75K | 09 Aug 2023 | Direct | ||
| Aquestive Therapeutics, Inc. | SVP, Chief Commercial Officer | Non-Qualified Stock Option (right to buy) | 40K | 04 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| AQST | Aquestive Therapeutics, Inc. | 09 Aug 2023 | 1 | $0 | 4 | SVP, Chief Commercial Officer | 09 Aug 2023, 16:30 |
| AQST | Aquestive Therapeutics, Inc. | 05 May 2023 | 1 | $0 | 4 | SVP, Chief Commercial Officer | 05 May 2023, 16:00 |
| AQST | Aquestive Therapeutics, Inc. | 09 Mar 2023 | 1 | $0 | 4 | SVP, Chief Commercial Officer | 09 Mar 2023, 14:07 |
| AQST | Aquestive Therapeutics, Inc. | 04 Nov 2022 | 1 | $0 | 4 | SVP, Chief Commercial Officer | 08 Nov 2022, 09:23 |
| AQST | Aquestive Therapeutics, Inc. | 10 Mar 2022 | 1 | $0 | 4 | SVP, Chief Commercial Officer | 14 Mar 2022, 11:25 |